2 results
Approved WMOCompleted
To test whether treatment with oral imatinib reduce disease burden and consumption of medical resources.
Approved WMORecruiting
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…